Evidence map›Paper›PMID 30596964›Full record

Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2019

Comparison of 3 Days Amoxicillin Versus 5 Days Co-Trimoxazole for Treatment of Fast-breathing Pneumonia by Community Health Workers in Children Aged 2-59 Months in Pakistan: A Cluster-randomized Trial.

Salim Sadruddin, Ibad Ul Haque Khan, Matthew P Fox, Abdul Bari, Attaullah Khan, Donald M Thea, Amanullah Khan, Inamullah Khan, Ijaz Ahmad, Shamim A Qazi

Open access · hybridAbstract readComparative StudyRandomized Controlled Trial
In one paragraph

Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Observational
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 4 countries.

Salim SadruddinWorld Health Organization, Geneva, Switzerland.
Ibad Ul Haque KhanMonitoring and Evaluation Consultant, Islamabad, Pakistan.
Matthew P FoxDepartment of Global Health, Boston University School of Public Health, Massachusetts.
Abdul BariIndependent Consultant, Islamabad.
Attaullah KhanDirectorate General, Health Services, Khyber Pakhtunkhwa.
Donald M TheaDepartment of Global Health, Boston University School of Public Health, Massachusetts.
Amanullah KhanWhite Ribbon Alliance, Islamabad.
Inamullah KhanUnited Nations International Children's Emergency Fund Peshawar.
Ijaz AhmadHealth Sector Reform Unit, Department of Health, Khyber Pakhtunkhwa, Pakistan.
Shamim A QaziIndependent Consultant, Geneva, Switzerland.
Boston University · USUnited Nations Children's Fund India · INWhite Ribbon Alliance · USGovernment of Khyber Pakhtunkhwa · PKInstitute of Business Leadership · PKWorld Health Organization · CH

Funding

Rates, Predictors and Mortality Impact of Losses from HIV Care in South AfricaK01AI083097 · NIAID · BOSTON UNIVERSITY MEDICAL CAMPUS · PI FOX, MATTHEW ALEXANDER PEASE · 2009 to 2013
$615k
NIAID NIH HHS K01 AI083097World Health Organization 001
6 · The paper itself

Abstract

backgroundGlobally, most deaths due to childhood pneumonia occur at the community level. Some countries are still using oral co-trimoxazole, despite a World Health Organization recommendation of oral amoxicillin for the treatment of fast-breathing pneumonia in children at the community level.

methodsWe conducted an unblinded, cluster-randomized, controlled-equivalency trial in Haripur District, Pakistan. Children 2-59 months of age with fast-breathing pneumonia were treated with oral amoxicillin suspension (50 mg/kg/day) for 3 days in 14 intervention clusters and oral co-trimoxazole suspension (8 mg trimethoprim/kg and 40 mg sulfamethoxazole/kg/day) for 5 days in 14 control clusters by lady health workers (LHW). The primary outcome was treatment failure by day 4 for intervention clusters and by day 6 for control clusters. The analysis was per protocol.

resultsOut of the 15 749 cases enrolled in the study, 9153 cases in intervention and 6509 cases in control clusters were included in the analysis. Treatment failure rates were 3.6% (326) in intervention clusters and 9.1% (592) in control clusters. After adjusting for clustering, the risk of treatment failure was lower in intervention clusters (risk difference [RD] -5.5%, 95% confidence interval [CI] -7.4--3.7%) than in control clusters. Children with incomplete adherence had a small increase in treatment failure versus those with complete adherence (RD 2.9%, 95% CI 1.6-4.1%). No deaths or serious adverse events occurred.

conclusionsA 3-day course of oral amoxicillin, administered by LHWs, is an effective and safe treatment for fast-breathing pneumonia in children 2-59 months of age. A shorter course of amoxicillin improves adherence to therapy, is low in cost, and puts less pressure on antimicrobial resistance. CLINICAL TRIALS REGISTRATION: ISRCTN10618300.

Indexed as

Administration, OralAmoxicillinAnti-Bacterial AgentsChild, PreschoolDrug Administration ScheduleFemaleHumansInfantInfant, NewbornMalePakistanPneumonia, BacterialRetrospective StudiesTreatment FailureTrimethoprim, Sulfamethoxazole Drug CombinationAmoxicillinAnti-Bacterial AgentsTrimethoprim, Sulfamethoxazole Drug Combinationcluster-randomized trialcommunity treatmentfast-breathing pneumoniaoral amoxicillinshort-course therapy

Identifiers

PMID30596964
PMCPMC6637273
OpenAlexW2907681283

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.